In December 2004, Xtrana, developing technologies to simplify the analysis of deoxyribonucleic acid (DNA) and ribonucleci acid (RNA), consummated a reverse merger with CA based Alpha Innotech, a provider of genetic analysis tools. Xtrana developed a unique new approach to DNA analysis, the Self Contained Integrated Particle (SCIP) cartridge. Xtrana, Inc. Formerly known as Biopool International, Inc.. and as Molecular Innovations Inc, the principal activity is to develop and commercialize technologies to simplify the analysis of DNA and RNA so that nucleic acid-based detection systems can be utilized in point-of-care, point-of-service applications. These technologies are designed to be easy to use outside of a traditional molecular biology laboratory. These diagnostic tests are intended for use in drug discovery, detection of environmental and food contaminants, forensics and identity testing, human and animal diseases, genetic predisposition to disease, and other applications. The trademarks of the Group include 'XTRANA,' 'Xtra Amp,' 'Xtra Bind,' and 'SCIP.' In December 2001, Trinity Biotech plc of Dublin, Ireland to acquired Xtrana's hemostasis business for $6.3 million in cash and notes
